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Chronic Q fever, caused by Coxiella burnetii, has high 
mortality and morbidity rates if left untreated. Controversy 
about the diagnosis of this complex disease has emerged 
recently. We applied the guideline from the Dutch Q Fe-
ver Consensus Group and a set of diagnostic criteria pro-
posed by Didier Raoult to all 284 chronic Q fever patients 
included in the Dutch National Chronic Q Fever Database 
during 2006–2012. Of the patients who had proven cas-
es of chronic Q fever by the Dutch guideline, 46 (30.5%) 
would not have received a diagnosis by the alternative cri-
teria designed by Raoult, and 14 (4.9%) would have been 
considered to have possible chronic Q fever. Six patients 
with proven chronic Q fever died of related causes. Until 
results from future studies are available, by which current 
guidelines can be modified, we believe that the Dutch lit-
erature-based consensus guideline is more sensitive and 
easier to use in clinical practice.
Coxiella burnetii is the causative agent of Q fever, a zoo-nosis occurring worldwide (1). Recently, a large epidem-
ic occurred in the Netherlands with >4,000 cases of acute Q 
fever notified from 2007 through 2010 (2,3). Chronic Q fe-
ver develops in an estimated 1%–5% of all infected humans 
and can become manifest even years after primary infection 
(1,4). Endocarditis and infection in aneurysms or vascular 
prostheses are the most common manifestations (1,5,6). Un-
treated chronic Q fever has a poor prognosis, with a reported 
mortality rate of up to 60% (1,7). Adequate antibiotic treat-
ment reduces the mortality rate for Q fever endocarditis to 
<5% (7). Treatment preferably consists of a combination of 
doxycycline and hydroxychloroquine for at least 18 months 
(nonprosthetic infection) to 24 months (prosthetic infection) 
and is recommended to be continued in case of unfavorable 
clinical or serologic response (7,8). Antibiotic guidelines for 
vascular chronic Q fever are not yet available, but antibiotic 
regimes for Q fever endocarditis have been applied to this 
disease entity as well. Early surgical intervention, with re-
moval of infected material, might improve the prognosis of 
vascular chronic Q fever (6,9).
In the early course of chronic Q fever, most patients 
are asymptomatic or experience nonspecific symptoms 
such as low-grade fever, night sweats, and weight loss 
(1,4,6,7). In the case of endocarditis, findings on echo-
cardiograph are often nonspecific or absent, which makes 
the diagnosis of chronic Q fever challenging (7). A PCR 
positive for C. burnetii or culture of the organism in blood 
or tissue, in the absence of acute Q fever, is a strong indi-
cator for chronic Q fever. However, sensitivity on blood 
samples is only 50%–60% for both PCR and culture in 
patients with chronic Q fever (10,11). Therefore, sero-
logic testing is also valuable for the diagnosis of chronic 
Q fever. A phase I IgG cutoff titer of 1:800, which is 
based on an in-house–developed immunofluorescence as-
say (IFA), has been internationally accepted for the diag-
nosis of chronic Q fever and is included in the modified 
Duke criteria for diagnosis of endocarditis (12,13). In the 
Netherlands, a commercial IFA (Focus Diagnostics, Inc., 
Cypress, CA, USA) is primarily used, with a proposed 
IgG cutoff value of 1:1,024 for chronic Q fever (14). Yet, 
recent studies show that serology results alone are not suf-
ficient for the diagnosis of chronic Q fever, but that they 
should be combined with clinical data (15).
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Dutch Consensus Guideline 
Faced with a large Q fever outbreak in the Netherlands and 
a rising number of (presumed) chronic Q fever patients, we 
were not able to find answers to all our questions about 
this complex disease in the literature. Moreover, random-
ized trials on diagnosis and treatment of this disease were 
lacking, and available data were not all applicable to the 
Dutch situation. For example, we found far more vascular 
localizations of chronic Q fever, with often severe com-
plications, than had been described previously. Therefore, 
the Dutch Q Fever Consensus Group was initiated in 2010, 
in which diagnosis and subsequent treatment consequences 
for suspected chronic Q fever were discussed. We per-
formed a thorough literature review and constructed a new 
guideline for the diagnosis of chronic Q fever, differentiat-
ing between proven, probable, and possible chronic Q fever 
(Table 1). We added advice for treatment and follow-up 
regimes for these 3 groups of patients. Antibiotic treatment 
and, if indicated, surgical treatment are recommended for 
all patients with proven chronic Q fever. The decision to 
start antibiotic treatment in patients with probable chronic 
Q fever depends on clinical characteristics and the condi-
tion of the patient, and should be determined by a multi-
disciplinary team. For possible chronic Q fever patients, 
antibiotic treatment should not be initiated, but follow-up 
is indicated.
After the Dutch consensus guideline was reported 
(14), a reaction by French researcher Didier Raoult was 
published; he did not agree with this proposed guideline 
and formulated alternative diagnostic criteria on the basis 
of his expert opinion (Table 2) (16). Professor Raoult is the 
undisputed leading authority on Q fever, and his opinion 
and the scientific publications from his research group 
should be considered by anyone working in the field of 
Q fever. Here, we attempt to resolve these differences of 
opinion by applying both criteria to cases from the Dutch 
National Chronic Q Fever Database.
Dutch Consensus Guideline versus Expert  
Opinion Guideline
A critical difference in the diagnostic criteria proposed by 
Raoult and those of the Dutch Q Fever Consensus Group 
is the diagnostic value attributed to C. burnetii PCR 
positivity of blood samples. Because we are unaware of 
clinical entities, other than acute and chronic Q fever, for 
which a PCR positive for C. burnetii in blood would be 
exhibited, we believe that positive blood PCR findings, in 
the absence of acute Q fever, prove chronic Q fever. The 
alternative criteria, on the other hand, state that a positive 
PCR finding in blood should be accompanied by a clear 
endocarditis focus shown on echocardiograph, a clear 
vascular focus on imaging studies, or at least 2 or 3 “mi-
nor criteria” (Table 2). Moreover, the alternative criteria 
attribute great value to the phase I IgG titer, proposing 
a phase I IgG ≥1:6,400 as a major criterion for Q fever 
endocarditis and Q fever vascular infection, in contrast to 
a phase I IgG ≥1:800 and <1:6,400 proposed as a minor 
criterion. This proposal contradicts the internationally ac-
cepted modified Duke criteria, which state that a phase 
I IgG ≥1:800 is a major criterion for infective (Q fever) 
endocarditis (13).
The alternative criteria also generally oppose the term 
chronic Q fever but makes a distinction in 2 manifestations: 
Q fever endocarditis and Q fever vascular infection. More 
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Table 1. Dutch consensus guideline on chronic Q fever diagnostics* 
Proven chronic Q fever Probable chronic Q fever Possible chronic Q fever 
1. Positive Coxiella burnetii PCR of blood 
or tissue† 
IFA ≥1:1,024 for C. burnetii phase I IgG‡ IFA ≥ 1:1,024 for C. burnetii phase I IgG‡ 
without manifestations meeting the criteria 
for proven or probable chronic Q fever OR AND any of the following: 
2. IFA ≥1:800 or 1:1,024 for C. burnetii 
phase I IgG† 
Valvulopathy not meeting the major criteria 
of the modified Duke criteria (13) 
AND Known aneurysm and/or vascular or 
cardiac valve prosthesis without signs of 
infection by means of TEE/ TTE, FDG-PET, 
CT, MRI, or AUS 
 
Definite endocarditis according to the 
modified Duke criteria (13) 
 
OR 
Proven large vessel or prosthetic infection 
by imaging studies (FDG-PET, CT, MRI, or 
AUS) 
Suspected osteomyelitis or hepatitis as 
manifestation of chronic Q fever 
 
Pregnancy  
Symptoms and signs of chronic infection, 
such as fever, weight loss and night 
sweats, hepato-splenomegaly, persistent 
raised ESR and CRP 
 
Granulomatous tissue inflammation, proven 
by histological examination 
 
Immunocompromised state  
*Source: (14). IFA, immunofluorescence assay; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; FDG-PET, 
fluorodeoxyglucose positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; AUS, abdominal ultrasound; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein. 
†In the absence of acute infection. 
‡Cut-off depends on the IFA technique used, whether in-house developed or commercial.  
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rare manifestations, such as pericarditis, hepatitis, and os-
teomyelitis, are left undefined, however.
After the recent outbreak of Q fever in the Netherlands, 
we initiated the Dutch National Chronic Q Fever Database, 
a joint effort by multiple hospitals in areas affected by Q fe-
ver, to monitor all chronic Q fever cases in the Netherlands. 
All hospitals with chronic Q fever patients, also outside the 
notified Q fever–epidemic areas, were actively approached. 
Design of the database and use of the collected information 
for analysis and scientific publications were approved by 
the Medical Research Ethics Committee of the University 
Medical Center Utrecht in Utrecht, the Netherlands. Part 
of these data had previously been published in a report dis-
cussing serologic profiles of patients with chronic Q fever 
(15).
Until the end of May 2012, a total of 284 patients 
had been included in our database (although the epidemic 
started in 2009, all patients from 2006 on are included): 
151 patients (53.2%) had proven chronic Q fever, 64 pa-
tients (22.5%) had probable chronic Q fever, and 69 pa-
tients (24.3%) had possible chronic Q fever, according 
to the Dutch consensus guideline. We reevaluated these 
chronic Q fever cases with the alternative diagnostic cri-
teria (Table 3). Of the case-patients with proven chronic Q 
fever according to the Dutch guideline, 46 (30.5%) would 
have been left undiagnosed with the alternative criteria. For 
cases of probable chronic Q fever, 58 cases (90.6%) would 
have been undiagnosed, and for possible cases of chronic 
Q fever, all 69 cases. 
The conditions of 8 patients with proven chronic Q fe-
ver (based on PCR positivity for C. burnetii in blood and 
suspicion of endocarditis) would have been diagnosed with 
possible Q fever endocarditis only by the alternative cri-
teria (Table 4). Eighteen patients with proven chronic Q 
fever would not have been diagnosed with Q fever endocar-
ditis at all, because echocardiography results did not match 
any major clinical Duke criterion, as is often observed in 
cases of Q fever endocarditis (7). Of the 8 patients with 
proven chronic Q fever endocarditis (by Dutch consensus 
guideline) who had been given a diagnosis of possible en-
docarditis according to the alternative criteria, 2 patients 
would have been considered to have definite endocarditis 
by the modified Duke criteria (13).
Twenty-four patients with a vascular C. burnetii in-
fection (Dutch consensus guideline) would not have been 
diagnosed with chronic Q fever by using the alternative cri-
teria (Table 4). Seventeen of these patients had a positive 
vascular lesion on fluorodeoxyglucose–positron emission 
tomography/computed tomography (FDG-PET/CT) with 
phase I IgG ≥1:800 and <1:6,400. Seven patients had a 
PCR of blood positive for C. burnetii, in combination with 
an aneurysm or vascular prosthesis but no signs of infec-
tion on FDG-PET/CT. According to the Dutch consensus 
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Table 2. Diagnostic guideline for chronic Q fever proposed  
by Raoult* 
Q fever endocarditis 
A. Definite criteria 
 Positive culture, PCR, or immunochemistry of a cardiac valve 
B. Major criteria 
 Microbiology: positive culture or PCR of the blood or an emboli  
 or serology with IgG I antibodies ≥6,400 
 Evidence of endocardial involvement:  
  Echocardiogram positive for IE: oscillating intra-cardiac  
  mass on valve or supporting structure, in the path of  
  regurgitant jets, or on implanted material in the absence of 
  an alternative anatomic explanation; or abscess; or new  
  partial dehiscence of prosthetic vale; or new valvular  
  regurgitation (worsening or changing of pre-existent murmur 
  not sufficient) 
  PET scan showing a specific valve fixation and mycotic  
  aneurysm 
C. Minor criteria 
 Predisposing heart condition (known or found on  
 echocardiograph) 
 Fever, temperature >38°C 
 Vascular phenomena, major arterial emboli, septic pulmonary  
 infarcts, mycotic aneurysm (see at PET scan), intracranial  
 hemorrhage, conjunctival hemorrhages, and Janeway lesions 
 Immunologic phenomena: glomerulonephritis, Osle nodes,  
 Roth spots, or rheumatoid factor 
 Serologic evidence: IgG I antibodies ≥800 <6,400 
Diagnosis definite 
 1. 1A criterion 
 2. 2B criterion 
 3. 1B, and 3C criterion 
Diagnosis possible 
 1. 1B criterion, 2C criteria (including microbiology evidence,  
  and cardiac predisposition) 
 2. 3C criteria (including positive serology, and cardiac  
  predisposition) 
Q fever vascular infection 
A. Definite criteria 
 Positive culture, PCR, or immunochemistry of an arterial  
 sample (prosthesis or aneurysm) or a periarterial abscess or a 
 spondylodiscitis linked to aorta 
B. Major criteria 
 Microbiology: positive culture or PCR of the blood or an emboli 
 or serology with IgG I antibodies ≥6,400 
 Evidence of vascular involvement  
 CT scan: aneurysm or vascular prosthesis + periarterial  
 abscess, fistula, or spondylodiscitis 
 PET scan: specific fixation on an aneurysm or vascular  
 prosthesis 
C. Minor criteria 
 Serological IgG I ≥800 <6,400 
 Fever, temperature >38°C 
 Emboli 
 Underlying vascular predisposition (aneurysm or vascular  
 prosthesis) 
Diagnosis definite 
 1. 1A criterion 
 2. 2B criterion 
 3. 1B and 2C criterion (including microbiology findings and  
  vascular predisposition) 
Diagnosis possible 
 Vascular predisposition, serological evidence and fever or  
 emboli 
*Source: (16). IE, infective endocarditis; PET, positron emission 
tomography; IFA, immunofluorescence assay; CT, computed tomography. 
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guideline, there were 5 patients with proven chronic Q fe-
ver with no known focus and 2 patients with Q fever with 
a focus other than endocarditis or vascular infection who 
would have been missed by using the alternative criteria. 
Five (repeatedly) had a positive C. burnetii PCR of blood 
but no clear infectious focus on echocardiograph and FDG-
PET/CT scan. One patient had a positive PCR in blood 
with clinical pericarditis, and 1 patient had a positive PCR 
in blood during pregnancy with phase I IgG >1:1,024 and a 
positive PCR of placental tissue. 
Notably, 10 patients with cases of proven chronic Q 
fever that were not diagnosed as definite chronic Q fever by 
the alternative criteria died (2 with possible chronic Q fever 
and 8 without chronic Q fever according to the alternative 
guideline). Six of these patients died due to clear chronic 
Q fever–related manifestations (2 with possible chronic Q 
fever and 4 without chronic Q fever according to the al-
ternative guideline, Table 4). The 2 patients with possible 
chronic Q fever died of complications caused by endocar-
ditis, one had a double-pathogen endocarditis with Staph-
ylococcus aureus. Two of the 4 patients without chronic 
Q fever according to the alternative guideline died due to 
aortoduodenal fistula, both with a phase I IgG >1:1024, but 
<1:6400, negative PCR on blood, and a clear FDG-positive 
vascular focus on PET/CT. In 1 of these 2 patients, Q fever 
vascular infection was confirmed postmortem with a posi-
tive PCR of the abdominal aortic aneurysm. No autopsy 
was performed on the other patient, unfortunately. The 
third patient, who had a history of a biologic heart valve 
replacement, an FDG-PET/CT negative aortic aneurysm, 
and a positive C. burnetii PCR of blood, eventually died of 
heart failure. Postmortem analysis demonstrated that PCR 
of the heart valve confirmed C. burnetii infection and thus 
Q fever endocarditis. Another chronic Q fever patient with 
positive PCR results of blood and minor valve lesions, ac-
cording to the Duke criteria, died of gastrointestinal bleed-
ing, probably due to aorto-intestinal fistula.
Conclusions
Several major differences exists between the Dutch consen-
sus guideline for the diagnosis of chronic Q fever and the 
alternative criteria. These alternative criteria define only Q 
fever endocarditis and Q fever vascular infection and op-
pose the term chronic Q fever. However, this distinction 
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Table 3. Comparison of chronic Q fever diagnosis according to the Dutch consensus guideline* and the alternative criteria† 
Alternative criteria  
Dutch consensus chronic Q fever guideline 
Proven, no. (%), n =151 Probable, no. (%), n = 64 Possible, no (%), n = 69 
Definite Q fever endocarditis 21 (13.9) 0 0 
Possible Q fever endocarditis 8 (5.3) 4 (6.3) 0 
Definite Q fever vascular infection 76 (50.3) 0 0 
Possible Q fever vascular infection 0 2 (3.1) 0 
No diagnosis of chronic Q fever 46 (30.5) 58 (90.6) 69 (100.0) 
*Source: (14). 
†Source: (16). 
 
 
 
 
Table 4. Characteristics and outcome of patients diagnosed with chronic Q fever using the Dutch consensus guideline* but without 
(definite) chronic Q fever according to alternative criteria† 
Dutch consensus guideline 
Alternative criteria 
Possible Q fever endocarditis or 
vascular infection, no. (%), n =14  
No diagnosis, no. (%), 
n = 173  
Proven Q fever 8 (57.1) 46 (26.6) 
 Endocarditis 8 (57.1) 18 (10.4); 
  PCR positive for Coxiella burnetii in blood 6 (42.9) 18 (10.4) 
  Evidence of endocardial involvement 2 (14.3) 0 
 Vascular infection 0 24 (13.9)‡ 
  PCR positive in blood 0 7 (4.0) 
  Vascular focus on imaging 0 17 (9.8) 
 Other or no focus§ 0 7 (4.1) 
 Deceased 2 (14.3) 8 (4.6) 
  Death probably due to Q fever 2 (14.3) 4 (2.3)¶ 
Probable Q fever 6 (42.9) 58 (33.5) 
 Endocarditis 4 (28.6) 22 (12.7) 
 Vascular infection 2 (14.3) 16 (9.3) 
 Other or no focus 0 20 (11.6) 
 Deceased 2 (14.3) 4 (2.3) 
  Death probably due to Q fever 1 (7.1) 0 
 Possible Q fever 0 69 (39.9) 
*Source: (14). 
†Source: (16). 
‡In 3 patients with proven chronic Q fever, imaging studies showed that the focus of infection was in both the heart valves and the vascular structures. 
§All were PCR positive. 
¶For 2 patients, PCR of vascular and heart valve tissue obtained at autopsy was  positive for C. burnetii.  
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is not accompanied by therapeutic consequences for each 
of these manifestations, which we believe makes these 
guidelines less practical.
It must be acknowledged that, because all patients in-
cluded in our study met the Dutch criteria for proven, prob-
able, or possible chronic Q fever, other guidelines can only 
perform with less accuracy in comparison. Nevertheless, 
sensitivity of the Dutch guideline is markedly higher than 
with the alternative criteria: ≈31% of proven chronic Q fe-
ver case-patients would have been missed as well as almost 
all patients with probable and possible cases, including at 
least 4 patients who eventually died of chronic Q fever re-
lated causes. Specificity of the Dutch consensus guideline 
is probably lower than that of the alternative criteria, but 
because mortality and morbidity rates are high when chron-
ic Q fever cases are untreated, we believe sensitivity is of 
greater importance in clinical practice. Our data illustrate 
that, when proven cases of chronic Q fever are missed, and 
patients are therefore not adequately treated, these patients 
are at high risk for severe complications and death.
As stated before, the most critical difference between 
the criteria of the Dutch guideline and those of the alterna-
tive guideline is the acknowledgment of a positive C. bur-
netii PCR as a marker of proven chronic Q fever in the ab-
sence of acute Q fever. Of course, this difference should be 
interpreted with care. In our opinion, patients without en-
docarditis or vascular infection on imaging studies but with 
a positive PCR in blood should also be treated for chronic 
Q fever, as they may suffer from not yet clinically visible 
endocarditis or vascular infection, which was confirmed by 
the postmortem results of 2 of our patients described above. 
A single positive C. burnetii PCR of blood is highly sug-
gestive for chronic Q fever when acute Q fever is excluded. 
A PCR test will not be performed in patients without symp-
toms and without any risk factors for chronic Q fever, so 
cases in whom a positive PCR is the only factor indicat-
ing chronic Q fever is a theoretical consideration. We have 
observed few patients, in the absence of signs of acute Q 
fever, with elevated phase I IgG titers not fulfilling the se-
rologic criteria of chronic Q fever (phase I IgG ≥1:800 or 
1,024) but with a positive C. burnetii PCR of blood or tis-
sue. In these cases, we are convinced that PCR-positivity 
proves chronic Q fever. No patients in our chronic Q fever 
database who had a positive PCR on blood or tissue had a 
phase I IgG titer of ≤1:256.
We agree with the statement that proven chronic Q fe-
ver will not develop in some patients with probable chronic 
Q fever and in most patients with possible chronic Q fe-
ver. We therefore do not advocate treating all of these pa-
tients with long-term antibacterial drugs. Nevertheless, we 
do think that these patients should all be examined for a 
chronic Q fever focus and should continue to be monitored 
closely, at least until further research offers more clarity 
regarding the prognosis of these patients. If these patients 
do not receive a diagnosis of possible or probable chronic Q 
fever, they might not receive such close follow-up. More-
over, the Dutch consensus guideline is easier to use, adds 
treatment advice, and also applies to patients with chronic 
Q fever manifestations that are rarer than endocarditis and 
vascular infection.
We hope that, with the future results from the Dutch 
National Chronic Q Fever Database and joint efforts of 
international researchers and experts in the field of Q fe-
ver, these guidelines can be modified to provide definite 
evidence-based criteria for diagnosis and treatment of this 
complex disease. In the meantime, the Dutch consensus 
guideline created on the basis of the scarce available lit-
erature is, in our opinion, safer and easier to use in clinical 
practice than the alternative expert-based criteria.
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